On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Search results for: psoriatic arthritis
The Rheumatologist Honored with 2 Awards of Excellence
We are honored to announce that The Rheumatologist has received two Awards of Excellence from APEX 2023 for content published in calendar year 2022: an Award of Excellence in the category of Public Health Concerns—Health & Medical for the editorial supplement to the April issue, COVID-19: What We Know, and an Award of Excellence for…
Measuring Up: A Review of the ACR-Owned Quality Measures
Since 2006, the Centers for Medicaid & Medicare Services (CMS) has increasingly driven clinicians to focus on and improve quality. Quality measures help clinicians measure how well they treat their patients. By tracking their performance, clinicians can identify opportunities to improve patient care while meeting federal reporting requirements. Breaking Down Quality Measures The CMS has…
Fellows in Training Learn & Network at ACR Convergence
PHILADELPHIA—The fellows-in-training (FIT) programs at ACR annual meetings are highly valued educational sessions that also offer a forum for fellows to meet and connect with trainees from other programs. Fellows who were not able to meet in person during the pandemic years, particularly those who were in their second or third year of training, welcomed…
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
How to Discuss Anti-Inflammatory Diets & Supplements with Your Patients
My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…
Methotrexate Shortage: Why It’s Happening & Potential Solutions
In recent months, many rheumatologists and rheumatology professionals have noted issues related to obtaining supplies of injectable and oral methotrexate for their patients with rheumatoid arthritis (RA). A conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), methotrexate is available as both oral tablets and as a subcutaneous injection for the treatment of RA and other autoimmune diseases.1…
The Effect of Upadacitinib on Bone Erosion in Patients with RA
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Research Update: Using Vagus Nerve Stimulation for Rheumatic Disease
Over the past decade, a number of pilot studies have provided proof of concept for the use of vagus nerve stimulation (VNS) to treat rheumatic conditions. The studies represent an expansion of this treatment approach into rheumatology, building on years of scientific inquiry into the mechanisms of VNS on disease states that led to preclinical…
Glucocorticoid Use May Result in Loss of Bone Mineral Density
Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 63
- Next Page »